Dauntless Investment Group LLC Invests $515,000 in aTyr Pharma, Inc. (NASDAQ:ATYR)

Key Points

• Dauntless Investment Group LLC invested $515,000 in aTyr Pharma, acquiring 170,689 shares, which represent about 0.6% of its portfolio.
• JPMorgan Chase & Co. significantly increased its stake in aTyr Pharma by 467.8%, now holding 178,532 shares valued at $646,000.
• aTyr Pharma's stock has seen a recent trading increase of 5.7%, with current market conditions reflecting a market capitalization of $548.24 million.

Dauntless Investment Group LLC acquired a new position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 170,689 shares of the company's stock, valued at approximately $515,000. aTyr Pharma accounts for about 0.6% of Dauntless Investment Group LLC's portfolio, making the stock its 23rd largest holding. Dauntless Investment Group LLC owned approximately 0.19% of aTyr Pharma as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its holdings in aTyr Pharma by 467.8% during the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock valued at $646,000 after purchasing an additional 147,092 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in aTyr Pharma during the 4th quarter valued at about $881,000. Charles Schwab Investment Management Inc. bought a new position in aTyr Pharma during the 4th quarter valued at about $144,000. Bank of America Corp DE bought a new position in aTyr Pharma during the 4th quarter valued at about $330,000. Finally, Jane Street Group LLC bought a new position in aTyr Pharma during the 4th quarter valued at about $720,000. 61.72% of the stock is owned by institutional investors.

aTyr Pharma Trading Up 5.7%

ATYR opened at $6.16 on Tuesday. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $548.24 million, a PE ratio of -7.60 and a beta of 0.89. aTyr Pharma, Inc. has a 1-year low of $1.67 and a 1-year high of $7.29. The firm has a 50-day moving average price of $5.13 and a two-hundred day moving average price of $4.03.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. As a group, equities analysts anticipate that aTyr Pharma, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ATYR shares. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company lifted their price target on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, June 20th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $20.20.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Want to see what other hedge funds are holding ATYR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.